---
$id: https://graph.org.ai/products/commodity/51111661
$type: Product
source: UNSPSC
code: "51111661"
title: "Troxacitabine"
class: "51111600"
classTitle: "Antimetabolites"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Troxacitabine

**UNSPSC Code**: 51111661
**Class**: [Antimetabolites](Antimetabolites.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a pyrimidine antagonist with the molecular formula C8H11N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60KQZ0388Y, chemically known as 2(1h)-pyrimidinone, 4-amino-1-((2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)- but generally known as troxacitabine, which bears US NIH Compound Identifier 151173. European Medicines Agency schedules Troxacitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22612. The term TROXACITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). Most nations schedule troxacitabine under HS 29349990 and SITC 51579. As of Q4 2014, TROXACITABINE remains the US FDA Preferred Term for this commodity. Troxacitabine bears US NLM identifiers UMLS ID C0877874 and NCI Concept Code C1438. SMILES: O1C(N2CCC(NC2=O)N)COC1CO.

